

Serial No.: 09/742,148
Filed: December 19, 2000

A-61008-1/RFT/TAL).

Please amend the application as follows and to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures in adherence with rules 37 C.F.R. § 1.821-1.825:

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 3, line 16, with the following rewritten paragraph:

C1
— Methods and compositions are provided for modulating lymphocytic activity, particularly CTL and NK cell activity, *in vitro* and *in vivo*. The compositions comprise oligopeptides of at least 6 amino acids comprising the tripeptide or triad (SEQ ID NO: 1) TYR-TYR-TRP (YYW), preferably the tetrapeptide (SEQ ID NO: 2) ARG-TYR-TYR-TRP (RYYW).—

Please replace the paragraph beginning at page 4, line 17, with the following rewritten paragraph:

C2
— For the most part, the oligopeptides will have at least 6, usually at least 8, amino acids, include the triad and come within the following formula: aa⁷⁰ aa⁷¹ Q aa⁷³ aa⁷⁴ R aa⁷⁶ aa⁷⁷ L aa⁷⁹ aa⁸⁰ aa⁸¹ aa⁸² aa⁸³ Y Y W aa⁸⁷ aa⁸⁸ aa⁸⁹ aa⁹⁰ aa⁹¹ (SEQ ID NO: 57).—

IN THE CLAIMS:

Please replace the section beginning on page 26, line 1, entitled "What Is Claimed Is" with the following rewritten section.

--WHAT IS CLAIMED IS:

1. (amended) A method of inhibiting activation of CTL and NK cells, said method comprising:

N.E.

*Claims 1-12 was canceled in
Amat-A